PRECISE PRO RX Nitinol Stent System
Cordis US Corporation · Decision date Jun 5, 2026
What did the FDA approve?
FDA records P030047/S055 as a supplement to PMA P030047, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Jun 5, 2026.
FDA approval order statement
Approval for labeling updates.
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Cardiovascular
- Decision date
- Jun 5, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P030047/S055
- Regulatory pathway
- PMA supplement
- Applicant
- Cordis US Corporation
- Product code
- NIM
- Decision code
- APPR
- Decision date
- Jun 5, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent, carotid.
- Applicant
- Cordis US Corporation
- Product code
- NIM
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P030047/S051 · Related supplement
PRECISE PRO RX Nitinol Stent System; PRECISE PRO Transcarotid Stent System
P030047/S052 · Related supplement
PRECISE PRO Rx Nitinol Stent System; PRECISE PRO Transcarotid Stent System
P030047/S053 · Related supplement
PRECISE PRO RX Nitinol Stent System; PRECISE PRO Transcarotid Stent System
P030047/S055 received
Application receipt date recorded by FDA.
P030047/S055 · FDA decision
Special (Immediate Track)
Timeline entries are records held by MedtechLedger for P030047. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030047
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cordis US Corporation | PMA supplement | Sep 12, 2025 | FDA | |
| Cordis US Corporation | PMA supplement | Oct 21, 2025 | FDA | |
| Cordis US Corporation | PMA supplement | Jan 8, 2026 | FDA |
Explore the linked device profile
Other records with product code NIM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PROTEGE GPS AND PROTEGE RX CAROTID STENT SYSTEMSP060001/S060 | Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA |
| Contego Medical, Inc. | PMA supplement | Nov 4, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Contego Medical, Inc. | PMA supplement | Jul 29, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Jul 10, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cordis US Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 14201 NW 60th Ave., Miami Lakes, FL, 33014
Sources and methodology
- Original FDA record: P030047/S055
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





